Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics announced a late-breaking poster presentation on LTI-03 at the ERS 2026 Congress, with data already pu | Sep 4, 2026 |
| CMND | 6-K | bearish | 7/10 | Clearmind Medicine, a $3M market-cap clinical-stage biotech, announced a definitive agreement to acquire a 51% controlli | Sep 4, 2026 |
| VRXA | PRESS-RELEASE | neutral | 2/10 | Veraxa Biotech announced the appointment of Raju Willener as CFO, effective immediately. Willener brings over 30 years o | Sep 4, 2026 |
| SNTI | 8-K | bearish | 6/10 | Senti Biosciences issued an additional $2.0M in Senior Secured Convertible Notes to NSG BioInnovation Fund and secured a | Sep 4, 2026 |
| EVAX | 6-K | bearish | 5/10 | Evaxion A/S raised $2.1M net through an at-the-market (ATM) offering of 681,268 ADSs at an average price of $3.1987 per | Sep 4, 2026 |
| DARE | EFFECT | bearish | 4/10 | Dare Bioscience's S-1 registration statement (File No. 333-298585) became effective on September 3, 2026, allowing the c | Sep 4, 2026 |
| GLMD | EFFECT | bearish | 5/10 | Galmed Pharmaceuticals' shelf registration (File No. 333-289703) was declared effective by the SEC on September 3, 2026. | Sep 4, 2026 |
| AVXL | DFAN14A | bullish | 7/10 | PVG Asset Management, a 327,344-share holder, issued an open letter and definitive proxy materials escalating its proxy | Sep 4, 2026 |
| IMRN | PRESS-RELEASE | neutral | 4/10 | Immuron announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a medical device for diges | Sep 4, 2026 |
| REGN | CLUSTER | neutral | 2/10 | Two Regeneron insiders (EVP Commercial and a director) sold a total of $1.37M in open-market shares over a three-day win | Sep 4, 2026 |
| TARS | CLUSTER | neutral | 2/10 | CEO Bobak Azamian and CMO Elizabeth Yeu sold a combined $928K in TARS shares over two days. The total represents just 0. | Sep 4, 2026 |
| MAZE | CLUSTER | neutral | 2/10 | Insider cluster at Maze Therapeutics shows CEO Jason Coloma and CSBO Atul Dandekar selling small amounts of stock over a | Sep 4, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Two ONC insiders (PAO Ball and COO Wu) sold a combined $153K in open-market transactions over a one-week window. The clu | Sep 4, 2026 |
| SLGL | INSIDER-BUY | bullish | 7/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, has purchased a total of $2.84M worth of SLGL shares in a | Sep 4, 2026 |
| CSTL | CLUSTER | bearish | 4/10 | Multiple C-suite insiders at Castle Biosciences sold shares totaling $195K in a cluster over the past week. The CEO, COO | Sep 4, 2026 |
| TRDA | CLUSTER | neutral | 3/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined $515K in open-market shares over a week, represen | Sep 4, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/General Counsel Paul Mahon sold a combined ~$5.8M in open-market shares over two days, pri | Sep 4, 2026 |
| SYRE | CLUSTER | bearish | 5/10 | CEO Cameron Turtle and CFO Scott Burrows sold a combined $810K in open-market sales on September 1, 2026. These sales fo | Sep 3, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Two Corcept Therapeutics insiders sold a combined $4.01M in stock over a week, including a Director's $3.27M sale. The t | Sep 3, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen | Sep 3, 2026 |
| MIST | 8-K | bullish | 6/10 | China's NMPA approved Milestone's etripamil nasal spray (CARDAMYST) for PSVT in adults, marking the first regulatory app | Sep 3, 2026 |
| ARTV | CLUSTER | bearish | 4/10 | Four Artiva insiders, including CEO Fred Aslan, sold a total of $912K in shares on September 3, 2026, all at $11.16. The | Sep 3, 2026 |
| TEVA | COURT-RULING | neutral | 2/10 | A federal magistrate judge in Kansas granted a motion to compel non-party law firm Goodwin Procter to produce two unreda | Sep 3, 2026 |
| BYSI | DEFA14A | neutral | 3/10 | BeyondSpring Inc. filed a DEFA14A (additional definitive proxy soliciting material) on September 3, 2026. The filing is | Sep 3, 2026 |
| GLMD | 6-K | neutral | 2/10 | Galmed Pharmaceuticals held its Annual General Meeting on September 3, 2026, and all proposals were approved by sharehol | Sep 3, 2026 |
| SEPN | 3 | neutral | 2/10 | Rajiv Patni, M.D., has been appointed Chief Medical Officer of Septerna, Inc. and filed a Form 3 initial statement of be | Sep 3, 2026 |
| PRTA | INSIDER-BUY | neutral | 3/10 | William P. Scully, a 10% owner of Prothena, purchased 27,000 shares on the open market for approximately $256K at $9.47/ | Sep 3, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two senior Alkermes executives (EVP/CLO and EVP R&D/CMO) sold a combined $521K in open-market shares over a 3-day window | Sep 3, 2026 |
| TEVA | COURT-RULING | neutral | 1/10 | The court denied a pro se plaintiff's appeal of a magistrate judge's order requiring her to appear in person for a depos | Sep 3, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two 10% owner entities (MPM BioVentures 2014 and 2018) sold a combined 88.5K shares for ~$619K in open-market sales over | Sep 3, 2026 |